On This episode of Stock Movers:

- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.

- Orsted said it’s considering “all options” including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday.

- Pets at Home Group named James Bailey, the former managing director of upmarket grocer Waitrose, as its new chief executive officer to lead a reboot of the struggling pet care company. 

On This episode of Stock Movers:
- Novo Nordisk won approval to sell a pill version of its blockbuster obesity shot Wegovy in the US, a crucial step in its effort to defend its market share from rival Eli Lilly.
- Orsted said it&rsquo;s considering &ldquo;all options&rdquo; including legal action as it weighs how to respond to a US decision to suspend leases for five offshore wind farms, according to a statement late Monday.
- Pets at Home Group named James Bailey, the former managing director of upmarket grocer Waitrose, as its new chief executive officer to lead a reboot of the struggling pet care company.&nbsp;

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for five-minute conversations on today's biggest winners and losers in the stock market. Subscribe for analysis on the companies making news on Wall Street.

Listen for news on today's biggest winners and losers in the stock market.

Stock Movers

Novo Nordisk's Pill, Orsted Winded, Pets At Home Up

https://api.omny.fm/orgs/e73c998e-6e60-432f-8610-ae210140c5b1/clips/ac303039-0a3c-45c5-a322-b3bc00962835/transcript

Advertisement